FRANKFURT (Reuters) – Germany will hold talks on whether it needs to make bulk purchases of Merck & Co’s promising drug candidate for the treatment of COVID-19, its health minister said on Wednesday.
Germany had always secured access to effective COVID-19 treatments early, minister Jens Spahn told a news conference, when asked whether the country would seek to buy Merck’s molnupiravir, which has shown promise in a trial.
(Reporting by Ludwig Burger and Riham Alkousaa)
